Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare

Vcare 2022 Annual Review

I. Corporate Development and Infrastructure 　　① Wholly-owned subsidiary Nanjing Vcare successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd. 　　② CDMO Business Technology Center completed and operational. 　　③ Established new technology platform laboratories. 　　④ Built a new Innovative Drug Synthesis Technology Center.

View Details

Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Series B to Accelerate Clinical Drug Development & CDMO Industrial Base

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed a Series B financing round exceeding CNY 200 million,which were led by Changjiang Venture Capital ,with participation from Hongcheng Capital and Hangzhou Huadian Investment, and continued support from Yangtze River Industry Group and SDIC Capital. The raised funds will be used to accelerate the clinical development of the company's core innovative drug products and the construction of its CDMO industrial base.

View Details

Jiangsu Vcare's Class 1 Novel Antiplatelet Drug Vicagrel Capsule Approved for Phase II Clinical Study in Ischemic Stroke

Recently, Vicagrel capsules, a Class 1 novel antiplatelet agent developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received Clinical Trial Approval from the NMPA for the target indication of minor ischemic stroke (MIS) or transient ischemic attack (TIA). The related Phase II clinical trial is set to begin shortly.

View Details

Jiangsu Vcare Closes Series A2 Financing

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.

View Details

First Dosing of Participant in the First Clinical Trial of Jiangsu Vcare's Highly Selective JAK1 Inhibitor VC005 Tablets

On November 19, 2021, the first clinical trial participant was dosed with VC005 tablets, a highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The dosing was completed at the Phase I Clinical Research Center of the First Hospital of Jilin University, and the participant has now successfully completed the safety observation period.

View Details

Initiation Meeting of FDA-FE Clinical Study of Vicagrel Capsules

On August 18, the kick-off meeting of the FDA-FE clinical study of Vicagrel Capsules, a Class I new drug of Jiangsu Vcare Pharmatech Co., Ltd. (Jaingsu Vcare), was held at the Phase I Clinical Research Center of the First Hospital of Jilin University. This marks the official launch of the FDA clinical study of Vicagrel in the United States and the supporting Phase III clinical study in China.

View Details